Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy

• US 8,415,318 B2
• Filed: 06/20/2011
• Issued: 04/09/2013
• Est. Priority Date: 10/19/2001
• Status: Expired due to Term

• Current Assignee: Vascular Biogenics Ltd.
• Original Assignee: Vascular Biogenics Ltd.
• Inventors: Harats, Dror, Greenberger, Shoshana, Breitbart, Eyal
• Primary Examiner(s): Ton, Thaian N
• Application Number:
  US13/163,767
• Publication Number:
  US 20110251122A1
• Time in Patent Office: 659 Days
• Field of Search: 514/44.R, 424/93.21, 435/455, 536/23.4
• US Class Current: 514/44.R
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 38/177 Receptors; Cell surface antigens; Cell surface determinants
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61K 38/191 Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2800/108 episomal vectors
• CPC Class Codes: C12N 2830/008 cell type or tissue specific enhancer/promoter combination
• CPC Class Codes: C12N 2830/15 chimeric enhancer/promoter combination
• CPC Class Codes: C12N 2830/85 mammalian
• CPC Class Codes: C12N 2840/20 translation of more than one cistron

Abstract

A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.

Claims

1. A method of inducing apoptosis of an endothelial cell in a tumor of a subject in need thereof, the method comprising administering to the subject a nucleic acid construct comprising:

(a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain of TNF Receptor 1 (TNFR1) fused to an effector domain of Fas; and

(b) a second polynucleotide region comprising a PPE-1-3X promoter, which directs expression of said chimeric polypeptide in the endothelial cell in the tumor;

wherein said chimeric polypeptide, when expressed, induces apoptosis of the endothelial cell in the tumor of said subject and wherein the nucleic acid construct is administered systemically or locally.

2. The method of claim 1, further comprising administering TNFα

to the subject.

3. The method of claim 1, wherein said administration is selected from the group consisting of:

(i) systemic in-vivo administration;

(ii) ex-vivo administration; and

(iii) local in-vivo administration.

4. The method of claim 1, wherein the ligand binding domain of TNFR1 comprises an extracellular domain of TNFR1.

5. The method of claim 1, wherein the effector domain of Fas comprises a trans-membrane region and an intracellular region of Fas.

6. The method of claim 1, wherein the ligand binding domain of TNFR1 is an extracellular domain of TNFR1 and the effector domain of Fas is a trans-membrane region and an intracellular region of Fas.

7. The method of claim 1, wherein the administration is parenteral administration.

8. The method of claim 3, wherein the systemic administration is intramuscular, subcutaneous, intramedullary, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, or intra-tumoral administration.

9. The method of claim 1, wherein the subject is characterized by excessive or abnormal neovascularization in the tissue or cell, thereby inducing tumor growth.

10. The method of claim 9, wherein the subject is a mammal.

11. The method of claim 9, wherein the subject is a human.

12. The method of claim 1, wherein the chimeric polypeptide induces apoptosis of the endothelial cell, wherein the size of the tumor is decreased.

13. The method of claim 2, wherein the TNF-α

is administered together with the nucleic acid construct.

14. The method of claim 1, wherein the tumor is a solid tumor.

15. The method of claim 1, wherein the tumor is a metastatic tumor.

16. The method of claim 1, wherein the nucleic acid construct comprises adenovirus.

17. The method of claim 1, wherein the nucleic acid construct comprises Ad-PPE-1-3X-Fas-chimera.

24. The method of claim 1, wherein the endothelial cell is in a blood vessel of the tumor.

25. The method of claim 1, wherein the chimeric polypeptide induces necrosis of the tumor.

26. The method of claim 12, wherein the chimeric polypeptide further induces necrosis of the tumor.

18. A method of inducing apoptosis of an endothelial cell in a tumor of a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a nucleic acid construct and a pharmaceutically acceptable carrier

wherein the nucleic acid construct comprises:

(a) a first polynucleotide region encoding a chimeric polypeptide comprising an extracellular domain of TNFR1 fused to a trans-membrane region and an intracellular region of Fas; and

(b) a second polynucleotide region comprising a PPE-1-3X promoter, which directs expression of said chimeric polypeptide in the endothelial cell in the tumor;

wherein said pharmaceutical composition induces apoptosis of the endothelial cell in the tumor of the subject and wherein the pharmaceutical composition is administered systemically or locally.

19. The method of claim 18, wherein the nucleic acid construct comprises Ad-PPE-1-3X-Fas-chimera.

20. The method of claim 18, wherein the pharmaceutical composition is administered intravenously or intra-tumorally.

21. A method of reducing a tumor size in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a nucleic acid construct and a pharmaceutically acceptable carrier,

wherein the nucleic acid construct comprises:

(a) a first polynucleotide region encoding a chimeric polypeptide comprising an extracellular domain of TNFR1 fused to a trans-membrane region and an intracellular region of Fas; and

(b) a second polynucleotide region comprising a PPE-1-3X promoter, which directs expression of said chimeric polypeptide in the tumor;

wherein said pharmaceutical composition reduces the tumor size in the subject and wherein the pharmaceutical composition is administered systemically or locally.

22. The method of claim 21, wherein the nucleic acid construct comprises Ad-PPE-1-3X-Fas-chimera.

23. The method of claim 21, wherein the pharmaceutical composition is administered intravenously or intra-tumorally.